scholarly journals Clinical trials in molecular radiotherapy—Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018

2019 ◽  
Vol 92 (1100) ◽  
pp. 20190117 ◽  
Author(s):  
Nadia Falzone ◽  
Rebecca Gregory ◽  
Matthew Aldridge ◽  
Samantha YA Terry ◽  
Glenn Flux
Keyword(s):  
Clinical Trials ◽  
Nuclear Medicine ◽  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy ◽  
Molecular Radiotherapy ◽  
Challenges And Opportunities ◽  
The Uk

It has been almost a decade since the commentary Molecular radiotherapy — the radionuclide raffle? by Gaze and Flux (2010). The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationally, of championing molecular targeted radionuclide therapy in all its aspects. Here, we report on the recent NCRI–CTRad (Clinical Trials in Molecular Radiotherapy–Tribulations and Triumphs) meeting, held in London on the 8 June 2018. The meeting was organized by the NCRI–CTRad to review the challenges and opportunities for clinical trials in molecular radiotherapy, particularly focussing on investigator-led trials that incorporate imaging and dosimetry, and to discuss how the community can move forward. This meeting was organised in conjunction with the British Nuclear Medicine Society and reflects the progress of Nuclear Medicine in the UK.

Bifunctional Chelators for Radiorhenium: Past, Present and Future Outlook

2022 ◽  
Author(s):  
Diana Melis ◽  
Andrew Burgoyne ◽  
Maarten Ooms ◽  
Gilles Gasser
Keyword(s):  
Nuclear Medicine ◽  
Cancer Treatment ◽  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy ◽  
Future Outlook ◽  
Bifunctional Chelators ◽  
Normal Tissues

Targeted radionuclide therapy (TRNT) is an ever-expanding field of nuclear medicine that provides a personalised approach to cancer treatment while limiting toxicity to normal tissues. It involves the radiolabelling of...

scholarly journals Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5776
Author(s):  
Elisabeth von Guggenberg ◽  
Petra Kolenc ◽  
Christof Rottenburger ◽  
Renata Mikołajczak ◽  
Alicja Hubalewska-Dydejczyk
Keyword(s):  
Clinical Trials ◽  
Radionuclide Therapy ◽  
Medullary Thyroid Cancer ◽  
Clinical Results ◽  
Targeted Imaging ◽  
Clinical Use ◽  
Targeted Radionuclide Therapy ◽  
Imaging Studies ◽  
Preclinical Development ◽  
Medullary Thyroid

The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development of CCK2R targeting compounds and the ongoing clinical trials are presented. Currently, new gastrin derivatives as well as nonpeptidic substances are being developed to improve the properties for clinical use. A team of specialists from the field of radiopharmacy and nuclear medicine reviewed the available literature and summarized their own experiences in the development and clinical testing of CCK2R targeting radiopharmaceuticals. The recent clinical trials with novel radiolabeled minigastrin analogs demonstrate the potential for both applications, imaging as well as targeted radiotherapy, and reinforce the clinical applicability within a theranostic concept. The intense efforts in optimizing CCK2R targeting radiopharmaceuticals has led to new substances for clinical use, as shown in first imaging studies in patients with advanced medullary thyroid cancer. The first clinical results suggest that the wider clinical implication of CCK2R-targeted radiopharmaceuticals is reasonable.

scholarly journals Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials

2019 ◽  
Vol 33 (11) ◽  
pp. 787-805 ◽  
Author(s):  
Makoto Hosono ◽  
Hideharu Ikebuchi ◽  
Seigo Kinuya ◽  
Sachiko Yanagida ◽  
Yoshihide Nakamura ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Nuclear Medicine ◽  
Radiation Protection ◽  
Radionuclide Therapy ◽  
Japanese Society ◽  
Radiation Safety ◽  
Japanese Version ◽  
Ministry Of Health ◽  
Safety Issues ◽  
Yttrium 90

Abstract We present the guideline for use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine. Treatment using yttrium-90-labeled anti-P-cadherin antibody injection in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown here are considered internationally useful as well. Only the original Japanese version is the formal document.

scholarly journals The Application of Nuclear Medicine

2016 ◽  
Vol 1 (2) ◽  
pp. 81
Author(s):  
Giner Maslebu ◽  
Suryasatriya Trihandaru
Keyword(s):  
Nuclear Medicine ◽  
Neutron Capture ◽  
Radionuclide Therapy ◽  
Hybrid Imaging ◽  
Cross Validation ◽  
Neutron Capture Therapy ◽  
Targeted Radionuclide Therapy ◽  
Diagnostic Modality ◽  
Definition Of ◽  
Radiopharmaceutical Therapy

Currently, the practice of nuclear medicine in modern countries comprises a large number of procedures. It is applied to study function of organs/body systems, to visualize, to characterize, and to quantify the functional state of lesions and for targeted radionuclide therapy. This overview presents all kinds of application in nuclear medicine services. Instrumentation and radioactive/radiolabeled substances are the basic components for application. Biotechnology contributes to the development and production of biomolecules used in radiopharmaceuticals. As a diagnostic modality, imaging depicts radioactivity distribution as a function of time. Hybrid imaging provides more precise localization and definition of le-sions as well as molecular imaging cross validation. Counting tests study invivo<br />organ functions externally or assess analytes in the biologic samples. Radiopharmaceutical therapy can be applied directly into the lesion or targeted systemically. Nanotechnology facilitates targeting and opens the development of bimodal techniques. In addition, neutron application contributes to the advancement of nuclear medicine services, such as neutron activation analysis, neutron teletherapy and neutron capture therapy.

Organs dosimetry in targeted radionuclide therapy

2021 ◽  
pp. 109668
Author(s):  
Meshari Alnaaimi ◽  
Abdelmoneim Sulieman ◽  
Mohammed Alkhorayef ◽  
Hasan Salah ◽  
Musa Alduaij ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy

scholarly journals Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities

2021 ◽  
Author(s):  
Rafael Dal-Ré ◽  
Linda-Gail Bekker ◽  
Christian Gluud ◽  
Søren Holm ◽  
Vivekanand Jha ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Challenges And Opportunities

scholarly journals Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

2021 ◽  
Vol 14 (7) ◽  
pp. 626
Author(s):  
Julie Bolcaen ◽  
Shankari Nair ◽  
Cathryn H. S. Driver ◽  
Tebatso M. G. Boshomane ◽  
Thomas Ebenhan ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Tyrosine Kinases ◽  
Radionuclide Therapy ◽  
Kinase Inhibitors ◽  
Nuclear Imaging ◽  
Therapy Resistance ◽  
Targeted Radionuclide Therapy ◽  
Therapy Strategy ◽  
Dismal Prognosis

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on tumor progression and therapy resistance. Therefore, receptor tyrosine kinase inhibitors (RTKIs) have been investigated to improve the dismal prognosis of GB in an effort to evolve into a personalized targeted therapy strategy with a better treatment outcome. Numerous RTKIs have been approved in the clinic and several radiopharmaceuticals are part of (pre)clinical trials as a non-invasive method to identify patients who could benefit from RTKI. The latter opens up the scope for theranostic applications. In this review, the present status of RTKIs for the treatment, nuclear imaging and targeted radionuclide therapy of GB is presented. The focus will be on seven tyrosine kinase receptors, based on their central role in GB: EGFR, VEGFR, MET, PDGFR, FGFR, Eph receptor and IGF1R. Finally, by way of analyzing structural and physiological characteristics of the TKIs with promising clinical trial results, four small molecule RTKIs were selected based on their potential to become new therapeutic GB radiopharmaceuticals.

Sign in / Sign up

Export Citation Format

Share Document